Prediction of Response to Preoperative Chemotherapy in Adenocarcinomas of the Esophagogastric Junction by Metabolic Imaging
Top Cited Papers
- 15 June 2001
- journal article
- gastrointestinal cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (12), 3058-3065
- https://doi.org/10.1200/jco.2001.19.12.3058
Abstract
PURPOSE: Preoperative chemotherapy in patients with gastroesophageal cancer is hampered by the lack of reliable predictors of tumor response. This study evaluates whether positron emission tomography (PET) using fluorine-18 fluorodeoxyglucose (FDG) may predict response early in the course of therapy. PATIENTS AND METHODS: Forty consecutive patients with locally advanced adenocarcinomas of the esophagogastric junction were studied by FDG-PET at baseline and 14 days after initiation of cisplatin-based polychemotherapy. Clinical response (reduction of tumor length and wall thickness by > 50%) was evaluated after 3 months of therapy using endoscopy and standard imaging techniques. Patients with potentially resectable tumors underwent surgery, and tumor regression was assessed histopathologically. RESULTS: The reduction of tumor FDG uptake (mean ± 1 SD) after 14 days of therapy was significantly different between responding (−54% ± 17%) and nonresponding tumors (−15% ± 21%). Optimal differentiation was achieved by a cutoff value of 35% reduction of initial FDG uptake. Applying this cutoff value as a criterion for a metabolic response predicted clinical response with a sensitivity and specificity of 93% (14 of 15 patients) and 95% (21 of 22), respectively. Histopathologically complete or subtotal tumor regression was achieved in 53% (eight of 15) of the patients with a metabolic response but only in 5% (one of 22) of the patients without a metabolic response. Patients without a metabolic response were also characterized by significantly shorter time to progression/recurrence (P = .01) and shorter overall survival (P = .04). CONCLUSION: PET imaging may differentiate responding and nonresponding tumors early in the course of therapy. By avoiding ineffective and potentially harmful treatment, this may markedly facilitate the use of preoperative therapy, especially in patients with potentially resectable tumors.This publication has 27 references indexed in Scilit:
- Utility of Positron Emission Tomography for the Staging of Patients With Potentially Operable Esophageal CarcinomaJournal of Clinical Oncology, 2000
- Chemotherapy Followed by Surgery Compared with Surgery Alone for Localized Esophageal CancerThe New England Journal of Medicine, 1998
- Classification of adenocarcinoma of the oesophagogastric junctionBritish Journal of Surgery, 1998
- Expression of the multidrug resistance protein (MRP) in squamous cell carcinoma of the oesophagus and response to pre-operative chemotherapyEuropean Journal of Cancer, 1998
- Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: A prospective randomized trialThe Journal of Thoracic and Cardiovascular Surgery, 1997
- Clinical value of diagnostic laparoscopy with laparoscopic ultrasound in patients with cancer of the esophagus or cardiaJournal of Gastrointestinal Surgery, 1997
- Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography.American Journal of Roentgenology, 1997
- Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucoseEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- Adenocarcinoma of the gastro-esophageal junction: CT for monitoring during neoadjuvant chemotherapyEuropean Journal of Radiology, 1996
- Response to Chemotherapy in Esophageal CancerEndoscopy, 1994